---
title: International Myeloma Working Group immunotherapy committee consensus guidelines
  and recommendations for optimal use of T-cell-engaging bispecific antibodies in
  multiple myeloma
date: '2024-05-02'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38697166/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20240503181535&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: Multiple myeloma remains an incurable disease, despite the development
  of numerous drug classes and combinations that have contributed to improved overall
  survival. Immunotherapies directed against cancer cell-surface antigens, such as
  chimeric antigen receptor (CAR) T-cell therapy and T-cell-redirecting bispecific
  antibodies, have recently received regulatory approvals and shown unprecedented
  efficacy. However, these immunotherapies have unique mechanisms of action and toxicities
  that ...
disable_comments: true
---
Multiple myeloma remains an incurable disease, despite the development of numerous drug classes and combinations that have contributed to improved overall survival. Immunotherapies directed against cancer cell-surface antigens, such as chimeric antigen receptor (CAR) T-cell therapy and T-cell-redirecting bispecific antibodies, have recently received regulatory approvals and shown unprecedented efficacy. However, these immunotherapies have unique mechanisms of action and toxicities that ...